Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Soluble epoxide hydrolase (sEH) converts epoxides to their corresponding diols. Inhibitors of sEH have anti-inflammatory, anti-hypertensive, neuroprotective, and cardioprotective effects.1,2 trans-AUCB is a very potent inhibitor of sEH (IC50 = 0.5 nM).3 It displays high oral bioavailability for doses ranging from 0.01 to 1 mg/kg.4,5 Dual inhibition of COX-2 and sEH, by celecoxib (Item No. 10008672) and trans-AUCB, suppresses tumor angiogenesis, inhibiting tumor growth and metastasis in a Lewis lung carcinoma model in mice.6
WARNING This product is not for human or veterinary use.
1. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA 102(28), 9772-9777 (2005).
2. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87(11), 992-998 (2000).
3. Synthesis and structure-
4. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur. J. Pharm. Sci. 40(3), 222-238 (2010).
5. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8(10), 794-805 (2009).
6. Dual inhibition of cyclooxygenase-